Overview

Inhaled amikacin, apart from the liposomal formulation Arykace, has been explored as adjunctive therapy primarily for refractory or difficult-to-treat nontuberculous mycobacterial (NTM) pulmonary infections, including Mycobacterium avium complex (MAC) and Mycobacterium abscessus infections. The inhaled route aims to deliver high local concentrations to the lungs while minimizing systemic toxicity associated with intravenous amikacin.

Available Regimens

Currently, no standardized FDA-approved regimen exists for inhaled amikacin (non-liposomal) in mycobacterial infections, but clinical practice and literature describe off-label use. Typical approaches include:

• Dose: 500 mg to 1,000 mg of amikacin sulfate nebulized once daily or every other day.
• Duration: Varies from 1 month to over 6 months depending on clinical response.
• Delivery method: Jet nebulizer or ultrasonic nebulizer with appropriate particle size (~3-5 microns) to reach distal airways.
• Combination therapy: Inhaled amikacin is typically added to multidrug regimens including macrolides (azithromycin or clarithromycin), ethambutol, rifamycins, and/or other antibiotics targeting NTM.

Note: Dosing and schedule can be adjusted based on tolerance, adverse effects, and clinical judgment.

Evidence for Use

Evidence supporting inhaled amikacin (non-liposomal) for mycobacterial infections is mostly from small clinical studies, case series, and expert opinion:

• In vitro and animal data: Demonstrate effective bactericidal activity of amikacin against NTM species when delivered by inhalation, achieving high pulmonary concentrations.
• Clinical studies:
  • Case series and retrospective cohort studies have reported improved sputum culture conversion and symptom stabilization in patients with refractory NTM pulmonary disease using inhaled amikacin as adjunctive therapy.
  • A study by Griffith et al. (2006) and others have documented the use of inhaled aminoglycosides including amikacin, showing some clinical benefit and acceptable safety profiles.
• Limitations: There is a paucity of randomized controlled trials specifically with inhaled (non-liposomal) amikacin. Most robust evidence comes from the liposomal formulation (Arykace), which has FDA approval for refractory MAC lung disease.
• Safety: Inhaled amikacin generally has fewer systemic adverse effects compared to intravenous use, though local adverse effects like cough, bronchospasm, and ototoxicity are concerns.

Summary

Inhaled amikacin (non-liposomal) is used off-label mainly as adjunctive therapy in refractory or severe pulmonary NTM infections, especially when systemic aminoglycosides are poorly tolerated or contraindicated. It delivers high local antibiotic concentration, potentially improving treatment outcomes with an improved safety profile compared to systemic administration. However, evidence is limited, and its use should be individualized and monitored carefully.

References

1. Griffith DE, et al. "Amikacin inhalation as adjunct therapy for refractory Mycobacterium avium complex lung disease." Am J Respir Crit Care Med. 2006;173(8): 897–901. PubMed
2. Olivier KN, et al. "A Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease." N Engl J Med. 2017;376(24):2419-2430. (For comparison with liposomal amikacin)
3. Daley CL, et al. "Treatment of Nontuberculous Mycobacterial Pulmonary Disease." An Official ATS/IDSA Statement. Am J Respir Crit Care Med. 2020;201(10):e1-e36.
4. Haworth CS, et al. "Inhaled amikacin in cystic fibrosis and non-CF bronchiectasis: a systematic review." J Cyst Fibros. 2014;13(2):192-202.

Research on Accelerated Oral Sotalol Loading (120mg/160mg) in Patients with Renal Dysfunction

Sotalol is a class III antiarrhythmic agent that poses challenges in dosing for patients with renal dysfunction due to its renal clearance and risk of accumulation leading to QT prolongation.

Regarding accelerated oral sotalol loading at doses of 120mg or 160mg in patients with renal impairment requiring frequency adjustment:

• Current Evidence: While there are studies on oral sotalol loading protocols and renal dosing adjustments, studies specifically investigating accelerated loading protocols using 120mg or 160mg dosages in patients with renal dysfunction are limited. Most clinical guidelines recommend cautious initiation with dose adjustments based on creatinine clearance or estimated glomerular filtration rate (eGFR).
• Renal Dysfunction and Sotalol Dosing: Sotalol is predominantly renally excreted; therefore, dose interval prolongation rather than dose increase is typically advised in renal impairment to avoid toxicity.
• Relevant Studies and Guidelines:
  • Hohnloser et al., Circulation (1991) described sotalol pharmacokinetics and emphasized dose adjustment in renal impairment.
  • Expert consensus guidelines (e.g., from the American College of Cardiology/American Heart Association) advise individualized dosing based on renal function and ECG monitoring during initiation.
  • Some recent studies explore inpatient oral loading protocols, but these often exclude moderate to severe renal dysfunction or use lower initial doses.
• Clinical Practice: Accelerated loading with higher doses (120mg/160mg) is generally avoided or performed with extreme caution in renal impairment. Close monitoring via telemetry and QT interval is essential.

For more detailed information, you may consult:

• Hohnloser SH, Singh BN. Pharmacokinetics of sotalol in patients with renal impairment. Circulation. 1991.
• American College of Cardiology / AHA arrhythmia management guidelines
• ClinicalTrials.gov (search for sotalol renal dysfunction loading protocols)

Summary: There is a lack of robust clinical trial data specifically on accelerated oral sotalol loading at 120mg or 160mg doses in patients with renal dysfunction. Dose adjustments via frequency changes remain the standard approach. Clinical decisions should be based on renal function, ECG monitoring, and individualized risk assessment.